Presentation is loading. Please wait.

Presentation is loading. Please wait.

SUPERIOR VENA CAVA SYNDROME Elesyia D. Outlaw March 9, 2004.

Similar presentations


Presentation on theme: "SUPERIOR VENA CAVA SYNDROME Elesyia D. Outlaw March 9, 2004."— Presentation transcript:

1 SUPERIOR VENA CAVA SYNDROME Elesyia D. Outlaw March 9, 2004

2 SVC Syndrome 4 Constellation of signs and symptoms caused by obstruction of blood flow in the superior vena cava. 4 Secondary to external compression, invasion, constriction or thrombosis of the SVC 4 Can be partial or complete obstruction

3 SCVS (cont) 4 Leads to increased venous pressure and results in edema of the head, neck, arms, and upper chest 4 Dilated veins on the chest wall 4 Pleural/pericardial effusions 4 Cerebral edema/Increased IC pressure

4 Patients

5

6 Clinical Features of SVC SYMPTOMSFREQUENCY Short of Breath50% Chest Pain20% Cough20% Dysphagia20% Markman, M. Cleveland Clinic Journal of Medicine, 1999

7 Clinical Features of SVCS SIGNSFREQUENCY Thorax Vein Distention70% Neck Vein Distention60% Facial Swelling45% UE/Trunk Swelling40% Cyanosis15% Markman, M. Cleveland Clinic Journal of Medicine, 1999

8 A/P #1

9 A/P #2 4 Formed by merger of left/right brachiocephalic veins + azygous 4 Venous blood from head/neck/upper extremities 4 6 to 8 cm in length 4 1.5 to 2 cm wide Abner, A. Chest, 1993

10 A/P #3 4 SVC surrounded by rigid structures (ie mediastinum, sternum, right mainstem bronchus and LN) 4 Thin walled and easily compressible secondary to low pressure 4 Prone to obstruction relative to its “neighbors”

11 A/P #4 4 As obstruction develops, venous collaterals form 4 Alternate pathways for venous return to the RA 4 Severity of sx depends on the time course of obstruction

12 SVCS

13 Etiology of SVC 4 Malignancy –Lung cancer –Lymphoma –Thymoma –Metastatic –Germ Cell 4 “Benign” –Infection/Inflammation –Benign Neoplasms –Iatrogenic –Trauma

14 Malignancy 4 Account for 80-97% of SVCS cases 4 Lung Cancer75-80% 4 Lymphoma10-15% 4 Others 5% –Metastatic –Thymoma –Germ cell tumor Markman, M. Cleveland Clin JOM, 1999. Ostler, P. Clin Onc, 1997.

15 Lung Cancer 4 5-10% Lung cancer pts develop SVCS 4 SCLC pts account for 50% SVCS in this group--yet only 25% of lung cancers 4 Tend to arise in central/perihilar 4 Right>>>>Left Markman, M. Cleveland Clin JOM, 1999. Ostler, P. Clin Onc, 1997.

16 Lymphoma 4 MD Anderson experience 4 915 pts treated for NHL 4 36 pts (3.9%) presented with SVCS 4 23 Diffuse LCL 4 12 Lymphoblastic 4 1Follicular LCL Perez-Soler, R. J Clin Onc, 1984.

17 Benign 4 1st case of SVCS described by William Hunter in 1757 4 Secondary to aortic aneurysm 2/2 syphilis 4 Pre-abx era---->approx 50% SVCS cases 4 Current----->3-5% SVCS cases

18 Mediastinitis 4 Histoplasmosis50% –Fibrosing mediastinitis 4 Others50% –TB –Actinomycosis –Syphilis –Post XRT Majahan, V. Chest, 1975

19 Benign Neoplasms 4 Substernal thyroid 4 Teratoma/Dermoid cysts 4 Benign Thymoma 4 Cystic hygroma

20 Iatrogenic 4 Thrombus formation 2/2 venous catheters 4 PM implantation 4 TPN lines 4 Swan-Ganz catheters 4 HD catheters Mahajan, V. Chest, 1975. Bertrand, M. Cancer, 1984.

21 Diagnosis 4 Chest radiograph 4 Duplex ultrasound 4 CT/MRI/MRV 4 Venogram 4 Radionuclide studies

22 Chest Radiograph CXR FINDINGSFREQUENCY Mediastinal Mass or Widening59-84% Hilar LAD19-50% Pleural Effusions 25% Armstrong, B. Int J Radiot Onc Biol Phys, 1987 Markman, M. Cleveland Clinic JOM, 1999 Parish, JM. Mayo Clin Proc, 1981

23 CT/MRI/MRV 4 Provide accurate info on location obstruction 4 Determine etiology of obstruction 4 Info on the extent of collaterals 4 Guide biopsy attempts

24 Venography 4 Can give precise level of obstruction 4 Less information on etiology of SVCS 4 Requires larger contrast dose 4 Usually done during IR mgmt

25 Tissue Diagnosis ProcedureYield Sputum cytology33-40% Bronchoscopy33-60% LN biopsy46-80% Mediastinoscopy 100% Thoracotomy 100% Ostler, J. Clin Onc, 1997 Schindler, N. Surg Clin N Am, 1999

26 Which First---> Tx or Dx? 4 Ahman 4 Literature search 1934-1984 4 1986 cases SVC reviewed 4 Only 1 clearly documented death 2/2 SVCS Ahman, F. J Clin Onc, 1984.

27 1st--->Tx or Dx? 843 inv dx procedComps 119 Thoractomies2 53Mediastinoscopies3 217Bronchoscopies2 120LN biopsies1 197Venograms1

28 Treatment 4 Tailored to etiology 4 Historically standard tx----->XRT 4 Emergent tx before tissue dx 2/2 presumed risk of bleeding 4 Current standard----> tissue dx prior to initiating tx

29 Treatment 4 Goal –treat symptoms –treat underlying cause 4 Tx should be tailored to histologic diagnosis---->determine if curative vs palliative

30 Treatment 4 Chemotherapy 4 XRT 4 Surgery 4 Interventional Procedures Spiro, S. Thorax, 1983 Perez-Soler, P. J Clin Onc, 1984

31 Treatment 4 Chemo vs XRT=equally effective 4 Combination of chemo/xrt did not improve response rate, symptoms or LT survival 4 Decreased LR in lymphoma but no change in OS Armstrong, B. Intl J RO Biol Phys, 1984. Perez-Stoler, P. J Clin Onc, 1984.

32 Surgical Tx

33 IR Treatment

34 IR Tx #2

35 IR Tx #3

36 IR Tx #4

37 Prognosis 4 Varies depending on the etiology 4 SVCS in its own right is rarely fatal 4 10-20% survive at least 2 years Ahman,F. J Clin Onc, 1984 Ostler, PJ. Clin Onc, 1997 Perez & Brady, 2004.

38 Prognosis 4 Reviewed 5052 patients tx at MIR 1/1965- 12/1984 4 125 patients tx SVCS 2/2 malignancy 4 Lung Cancer 79%, Lymphoma 18%, Other 6% 4 XRT+/- chemotherapy Armstrong, B. Int J Radiot Onc Biol Phys, 1987

39 Prognosis Overall 4 Median Survial=5.5 months 4 1 year survival=24% 4 5 year survival= 9% Armstrong, B. Int J Radiot Onc Biol Phys, 1987

40 Prognosis-SCLC 4 1 year survival=24% 4 5 year survival= 5% Armstrong, B. Int J Radiot Onc Biol Phys, 1987

41 Prognosis-Lymphoma 4 1 year survival=41% 4 5 year survival=41% Armstrong, B. Int J Radiot Onc Biol Phys, 1987

42 Prognosis-NSLC 4 1 year survival=17% 4 2 year survival= 2% Armstrong, B. Int J Radiot Onc Biol Phys, 1987

43 Prognosis 4 No statistical difference in survival rates between patients treated with chemoradiation vs either tx alone 4 Pts who responding clinically within 30days of treatment had better 1 year survival (27% vs 7%) Armstrong, B. Int J Radiot Onc Biol Phys, 1987

44 Prognosis-BSVCS 4 Depends on collateral circulation 4 20-50 years GreenbergA. Ann Thorac Surg, 1985 Mahajan, V. Chest, 1975 Murdock, W. Scott Med J, 1960


Download ppt "SUPERIOR VENA CAVA SYNDROME Elesyia D. Outlaw March 9, 2004."

Similar presentations


Ads by Google